Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Nelarabine

Nature Reviews Drug Discovery volume 5, pages 17–18 (2006)Cite this article

Abstract

In October 2005, nelarabine (Arranon; GlaxoSmithKline), a nucleoside analogue, was given accelerated approval by the US FDA for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded to treatment or has relapsed following treatment with at least two chemotherapy regimens.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Ara-G and nelarabine.

References

  1. Pui, C.-H. & Evans, W. E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605–615 (1998).

    Article  CAS  Google Scholar 

  2. Parker, W. B. et al. Purine nucleoside analogues in development for the treatment of cancer. Curr. Opin. Investig. Drugs 5, 592–596 (2004).

    CAS  PubMed  Google Scholar 

  3. Rodriguez, C. O. et al. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 102, 1842–1848 (2003).

    Article  CAS  Google Scholar 

  4. Krenitsky, T. A. et al. An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydr. Res. 97, 139–146 (1981).

    Article  CAS  Google Scholar 

  5. Lambe, C. U. et al. 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 55, 3352–3356 (1995).

    CAS  PubMed  Google Scholar 

  6. Rodriguez, C. O. et al. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 59, 4937–4943 (1999).

    CAS  PubMed  Google Scholar 

  7. Gandhi, V. et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol. 16, 3607–3715 (1998).

    Article  CAS  Google Scholar 

  8. Gandhi, V. et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J. Clin. Oncol. 19, 2142–2152 (2001).

    Article  CAS  Google Scholar 

  9. Kurtzberg, J. et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 23, 3396–3403 (2005).

    Article  CAS  Google Scholar 

  10. Berg, S. L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J. Clin. Oncol. 23, 3376–3382 (2005).

    Article  CAS  Google Scholar 

  11. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021877lbl.pdf> (2005).

  12. Carson, D. A. et al. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J. Immunol. 121, 1726–1731 (1978).

    CAS  PubMed  Google Scholar 

  13. Cohen, A. et al. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 61, 660–666 (1983).

    CAS  PubMed  Google Scholar 

  14. Shewach, D. S. et al. Metabolism and selective cytotoxicity of 9-β-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 45, 1008–1014 (1985).

    CAS  PubMed  Google Scholar 

  15. Ullman, B. & Martin, D. W. J. Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J. Clin. Invest. 74, 951–955 (1984).

    Article  CAS  Google Scholar 

  16. Shewach, D. S. & Mitchell, B. S. Differential metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells. Cancer Res. 49, 6498–6502 (1989).

    CAS  PubMed  Google Scholar 

  17. Kisor, D. F. et al. The pharmacokinetics of 506U78 and ara-G in pediatric and adult patients during a Phase I study of 506U78 for the treatment of refractory hemato-logic malignancies. J. Clin. Oncol. 18, 995–1003 (2000).

    Article  CAS  Google Scholar 

  18. O'Brien, S. et al. Compound 506 has activity in mature lymphoid leukemia. Blood 92, 490a (1998).

    Google Scholar 

  19. IMS Health Analysis, IMS MIDAS Quantum, MAT (June 2005) and IMS Oncology Analyzer.

Download references

Author information

Authors and Affiliations

  1. the University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, 77030, Texas, USA

    Varsha Gandhi & Michael J. Keating

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Guy Bate

  3. Nature Reviews Drug Discovery, UK

    Peter Kirkpatrick

Authors
  1. Varsha Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guy Bate
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gandhi, V., Keating, M., Bate, G. et al. Nelarabine. Nat Rev Drug Discov 5, 17–18 (2006). https://doi.org/10.1038/nrd1933

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1933

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing